Angiotensin Converting Enzyme Market Size & Growth Analysis to 2030

The global angiotensin converting enzyme (ACE) market size is projected to grow at a passive CAGR of less than 1% during 2020-2027 and expected to reach over USD 12 billion in terms of revenue by 2027. The renin-angiotensin-aldos-terone system (RAAS) plays a key physiologic role in the regulation of blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II where it facilitates the conversion of the biologically inactive angiotensin I to angiotensin II.

The key factors supporting the ACE inhibitors market are the rising prevalence of hypertension and diabetes, and high public awareness related to early diagnosis and management of lifestyle disorders. ACE inhibitors also play a key role in the treatment of chronic kidney diseases and other cardiovascular diseases such as heart failure and myocardial infarction. In the case of several applications of ACE inhibitors chronic kidney disorders segment was observed as the fastest moving segment in overall ACE inhibitors market throughout the forecast period 2020 – 2027. According to the World Bank, by year 2025 the global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures.

Market Insights:

ACE inhibitors are responsible for blocking the conversion of angiotensin I to angiotensin II, used in the treatment of hypertension and congestive heart failure. The global statistics published by the World Health Organization (WHO) suggests that globally cardiovascular disease is responsible for approximately 17 million deaths a year, nearly one-third of the total. Out of these deaths, complications of hypertension account for 9.4 million deaths worldwide every year. ACE inhibitors market can be segmented on the basis of the type of drug and application. The type of drug segment comprises of benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors.  The key applications of ACE inhibitors comprise hypertension, coronary artery disease, heart failure, myocardial infarction, diabetes, chronic kidney disorders, and others (scleroderma, migraine, and others). It was observed that around 40% of the market share was owned by hypertension due to the rising prevalence of hypertension, high efficacy of ACE inhibitors in hypertension treatment.

The geographical segmentation comprises regions such as North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. North America accounted for the largest market share due to key market driving factors such as the rising prevalence of cardiovascular and kidney diseases, peaking obesity in the population due to sedentary lifestyle, and supportive reimbursement policies. The other factors responsible for North America’s domination are developed healthcare infrastructure, and high public awareness related to diagnosis, treatment, and management of lifestyle diseases.

Market Segment Insights:

The global angiotensin converting enzyme (ACE) market is segmented by drug type, and application. Based on drug type, this market is categorized into benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. Market experts suggest that lisinopril and ramipril are most popular than comparable drugs due to dosage convenience, good insurance coverage, and higher efficiency along with low side-effects. Angiotensin-converting enzyme finds major adoption in hypertension, coronary artery diseases, heart failure, myocardial infarction, diabetes, chronic kidney disorders, & (scleroderma, migraine, and others). The rising prevalence of hypertension and diabetes and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market. The chronic kidney disorders application segment is anticipated to be the fastest moving segment in the overall ACE inhibitors market throughout the forecast period 2020 – 2027.

Global Angiotensin Converting Enzyme (ACE) Market Segmentation:

By Drug Type, 2018–2027 ($ Millon)

• Benazepril
• Captopril
• Enalapril
• Fosinopril
• Lisinopril
• Moexipril
• Perindopril
• Quinapril
• Ramipril
• Trandolapril
• Combination ACE Inhibitors

By Application, 2018-2027 ($ Millon)

• Hypertension
• Coronary Artery Diseases
• Heart Failure
• Myocardial Infarction
• Diabetes
• Chronic Kidney Disorders
• Others (Scleroderma, Migraine and others)

By Geography, 2018-2027 ($ Millon)

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Regional Insights:

As of the current market scenario, North America was observed as the largest and most potential regional market for ACE inhibitors. The rising prevalence of hypertension and kidney disorders, developed healthcare infrastructure, high public awareness related to lifestyle diseases and treatment, and rising research and development activities related to the management of lifestyle diseases are the key factors assisting the North America ACE inhibitors market. During the forecast period 2020 -2027, Asia-Pacific was observed as the fastest growing regional market for the ACE inhibitors market. Over the next eight years, the growth of the market in the Asia-Pacific region is likely to be centered in China, India, and Japan. Several factors such as the rising prevalence of hypertension and kidney disorders along with high public awareness related to the diagnosis of lifestyle diseases is assisting the growth of the Asia Pacific market.

Market Competition Assessment:

Key players in the global angiotensin converting enzyme (ACE) market are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

List of Key Companies:

• Abbott Laboratories
• Pfizer, Inc.
• Novartis AG
• Merck & Co.
• Astra Zeneca plc
• Jhonson and Johnson Limited
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb Company
• Bayer AG
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Other Notable Players

Key Questions Answered by Angiotensin Converting Enzyme Market Report

• Global angiotensin-converting enzyme market forecasts from 2020-2027
• Regional angiotensin-converting enzyme market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2020-2027 covering 15 major countries from the aforementioned regions
• Angiotensin-Converting Enzyme submarket forecasts from 2020-2027 covering submarket 1, submarket 2 submarket 3
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to the angiotensin-converting enzyme market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level angiotensin-converting enzyme markets from 2020-2027
• Competitive Landscape and market positioning of top 10 players operating in the angiotensin-converting enzyme market

Request a Full Report PDF Sample @ https://www.researchcorridor.com/request-sample/?id=137242